A Study of TTYP01 in Healthy Adult Subjects

Summary

This is integrated Phase 1, Single centre, Randomized study will be conducted in 3 parts, each with a specific primary objective:

Part A: To characterise the safety and tolerability of TTYP01 in healthy adult subjects; Part B: To evaluate the bioavailability of TTYP01 tablets in healthy adult subjects; Part C: To characterise the food effect of TTYP01 tablets in healthy adult subjects under the fasted or fed condition.

The secondary objectives of the study are to evaluate the pharmacokinetic (PK) profiles of TTYP01 tablets in healthy adult subjects, and the effects of gender on the PK of TTYP01 tablets in healthy adults. In Part A of the study, a total of 32 healthy adult subjects will be enrolled over four consecutive cohorts (8 per cohort), with participants receiving a single dose of TTYP01 at one of four levels (60, 120, 10 or 240 mg), to assess the PK and safety of TTYP01. In Part B, 16 healthy adults will be randomized into 2 groups, and the comparison of the PK of edaravone (TTYP01 and intravenous (IV) edaravone) will be evaluated using a randomized, open-label, four-period crossover design under fasted conditions. In the first crossover period, subjects will receive a single fixed dose of TTYP01 followed by the alternate IV dose after completion of the washout phase, and in the second crossover period, subjects will receive a higher fixed dose of TTYP01 followed by the alternate IV dose after completion of the washout phase. In Part C, 18 healthy subjects will be enrolled to evaluate the effect of food on the PK of TTYP01 using a randomized, open-label, two-period cross-over design. Participants will be randomized into two groups and administered a fixed dose of TTYP01 on Day 1 (Period 1) under the fed conditions and the second dosing day (Period 2) under the fasted conditions, while the other group being administered a fixed dose of TTYP01 on Day 1 (Period 1) under the fasted conditions and the second dosing day (Period 2) under the fed conditions.

Conditions

• Healthy Adult Subjects

Interventions

DRUG

Placebo

Placebo control for Part A of the study

DRUG

TTYP01, 60 mg

TTYP01 oral tablets (30 mg edaravone per tablet)

DRUG

TTYP01, 120 mg

TTYP01 oral tablets (30 mg edaravone per tablet)

DRUG

Radicut® (ampoule), 30 mg

An intravenous dose of edaravone injection, containing 30 mg edaravone in a 20 mL ampoule, will be administered at a dose of 30 mg over 30 minutes

DRUG

Radicut® (bag) , 60 mg

An intravenous dose of edaravone injection, containing 30 mg edaravone in a 100 mL injection bag, will be administered at a dose of 60 mg over 60 minutes

DRUG

TTYP01, up to 120 mg

TTYP01 oral tablets (30 mg edaravone per tablet). The fixed oral dose level of TTYP01 will depend on the results obtained in Part B of the study (no more than 120 mg)

DRUG

TTYP01 single ascending doses

TTYP01 (30 mg edaravone tablet) will be orally administrated at single ascending doses of 60 mg, 120 mg, 180 mg and 240 mg (n=6 per dose)

Sponsors & Collaborators

• TIGERMED AUSTRALIA PTY LIMITED

  collaborator UNKNOWN

• CMAX Clinical Research Pty Ltd

  collaborator UNKNOWN

• Shanghai Auzone Biological Technology Co., Ltd.

  lead INDUSTRY

Principal Investigators

• Sepehr Shakib, MD · Royal Adelaide Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

40 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2020-04-24

Primary Completion

2020-12-17

Completion

2021-01-08

Countries

• Australia

Study Locations